Novel Fights 'Patient' Claim Rehearing In Suprep Suit

Law360, New York (July 7, 2014, 7:22 PM EDT) -- Generic drug producer Novel Laboratories Inc. urged the Federal Circuit on Thursday to deny Braintree Laboratories Inc.’s bid for an en banc rehearing on the construction of the term “a patient” in its Suprep colon cleanser patent, saying the court properly rendered the claim to mean a “patient population.”

In response to Braintree’s May petition for a panel rehearing, Novel argues that the Federal Circuit correctly ruled that the term “a patient” in U.S. Patent Number 6,946,149 applied to the general class of persons to whom...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Braintree Laboratories, Inc. v. Novel Laboratories, Inc.


Case Number

13-1438

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

June 10, 2013

Law Firms

Government Agencies

Patents

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.